MedTrace Logo

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

NCT03282149 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-07-05

No results posted yet for this study

Summary

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain - Dose escalation

Conditions

  • Osteoarthritis, Knee

Interventions

BIOLOGICAL

XT-150

IL-10 transgene DNA plasmid injected into the knee synovial capsule

Sponsors & Collaborators

  • Xalud Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Rickman, MD · University of Adelaide

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-21
Primary Completion
2019-03-31
Completion
2019-06-15
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03282149 on ClinicalTrials.gov